|
Aug 7
|
Viridian Therapeutics Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 6
|
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 6
|
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
|
|
Jul 30
|
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
|
|
Jul 27
|
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings
|
|
Jul 15
|
Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial
|
|
May 7
|
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
|
|
May 7
|
Viridian Therapeutics First Quarter 2025 Earnings: Beats Expectations
|
|
May 6
|
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
|
|
Sep 10
|
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
|
|
Sep 10
|
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
|
|
Sep 9
|
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
|
|
Aug 8
|
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
|
|
Jul 25
|
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
|
|
May 10
|
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
|
|
May 9
|
Viridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 9
|
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 8
|
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements
|
|
May 8
|
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
|
|
Apr 29
|
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
|